Lightlake appoints VP, medical affairs
This article was originally published in Scrip
Executive Summary
Lightlake Therapeutics, a biopharmaceutical company developing addiction treatments using opioid antagonists, has named Arvind Agrawal executive vice-president of medical affairs. During his career, Mr Agrawal has overseen, managed, and delivered global Phase I-IV clinical studies and has experience in the therapeutic areas of addiction, psychiatry, CNS, respiratory, cardiovascular, and diabetes. Prior to joining Lightlake, he was head of medical affairs for new products at Mundipharma.